Review article
Ethical considerations in presymptomatic diagnosis of autosomal dominant spinocerebellar ataxias
Consideraciones éticas en el diagnóstico presintomático de ataxias espinocerebelosas autosómico dominantes
a Maestría en Ciencias, Instituto de Genética Humana Dr. Enrique Corona Rivera, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
b Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
c Instituto de Desarrollo en Ciencia e Investigación Biomédica S.C., Guadalajara, Jalisco C.P. 44680, Mexico
Read
3437
Timeswas read the article
808
Total PDF
2629
Total HTML
Share statistics
array:25 [ "pii" => "S2173580817300652" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2015.06.018" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "768" "copyright" => "Sociedad Española de Neurología" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Neurologia. 2017;32:469-75" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 929 "formatos" => array:3 [ "EPUB" => 65 "HTML" => 627 "PDF" => 237 ] ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0213485315001553" "issn" => "02134853" "doi" => "10.1016/j.nrl.2015.06.004" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "768" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Neurologia. 2017;32:469-75" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1431 "formatos" => array:3 [ "EPUB" => 55 "HTML" => 980 "PDF" => 396 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Consideraciones éticas en el diagnóstico presintomático de ataxias espinocerebelosas autosómico dominantes" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "469" "paginaFinal" => "475" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ethical considerations in presymptomatic diagnosis of autosomal dominant spinocerebellar ataxias" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.H. Orozco-Gutiérrez, I. Cervantes-Aragón, D. García-Cruz" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M.H." "apellidos" => "Orozco-Gutiérrez" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Cervantes-Aragón" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "García-Cruz" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173580817300652" "doi" => "10.1016/j.nrleng.2015.06.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580817300652?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485315001553?idApp=UINPBA00004N" "url" => "/02134853/0000003200000007/v1_201708280004/S0213485315001553/v1_201708280004/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2173580817300998" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2015.11.012" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "814" "copyright" => "Sociedad Española de Neurología" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Neurologia. 2017;32:476-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1290 "formatos" => array:3 [ "EPUB" => 58 "HTML" => 1043 "PDF" => 189 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Bilateral anterior ischaemic optic neuropathy in a patient with haemochromatosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "476" "paginaFinal" => "477" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Neuropatía óptica isquémica anterior bilateral en paciente con hemocromatosis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Cifuentes-Canorea, R. Gutierrez-Bonet, J. García-Feijoo, E. Santos-Bueso" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Cifuentes-Canorea" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Gutierrez-Bonet" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "García-Feijoo" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Santos-Bueso" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485315002443" "doi" => "10.1016/j.nrl.2015.11.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485315002443?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580817300998?idApp=UINPBA00004N" "url" => "/21735808/0000003200000007/v1_201708280004/S2173580817300998/v1_201708280004/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2173580817300986" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2015.03.020" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "743" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Neurologia. 2017;32:463-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1591 "formatos" => array:3 [ "EPUB" => 63 "HTML" => 1188 "PDF" => 340 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Epigenetic changes in neurology: DNA methylation in multiple sclerosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "463" "paginaFinal" => "468" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Modificaciones epigenéticas en neurología: alteraciones en la metilación del ADN en la esclerosis múltiple" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1060 "Ancho" => 1643 "Tamanyo" => 87048 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">DNA methylation: diagram of the metabolic pathway involved in DNA methylation. DNMT: DNA methyltransferases; HC: homocysteine, MAT: methionine adenosyltransferase; MET: methionine; SAH: S-adenosyl-<span class="elsevierStyleSmallCaps">l</span>-homocysteine; SAHH: S-adenosyl-<span class="elsevierStyleSmallCaps">l</span>-homocysteine hydrolase; SAM: S-adenosyl-<span class="elsevierStyleSmallCaps">l</span>-methionine; THF: tetrahydrofolate; 5-MTHF: 5-methyltetrahydrofolate.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Iridoy Zulet, L. Pulido Fontes, T. Ayuso Blanco, F. Lacruz Bescos, M. Mendioroz Iriarte" "autores" => array:5 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Iridoy Zulet" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Pulido Fontes" ] 2 => array:2 [ "nombre" => "T." "apellidos" => "Ayuso Blanco" ] 3 => array:2 [ "nombre" => "F." "apellidos" => "Lacruz Bescos" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Mendioroz Iriarte" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485315000638" "doi" => "10.1016/j.nrl.2015.03.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485315000638?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580817300986?idApp=UINPBA00004N" "url" => "/21735808/0000003200000007/v1_201708280004/S2173580817300986/v1_201708280004/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Ethical considerations in presymptomatic diagnosis of autosomal dominant spinocerebellar ataxias" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "469" "paginaFinal" => "475" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M.H. Orozco-Gutiérrez, I. Cervantes-Aragón, D. García-Cruz" "autores" => array:3 [ 0 => array:3 [ "nombre" => "M.H." "apellidos" => "Orozco-Gutiérrez" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 1 => array:3 [ "nombre" => "I." "apellidos" => "Cervantes-Aragón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:4 [ "nombre" => "D." "apellidos" => "García-Cruz" "email" => array:1 [ 0 => "dianagarcr@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Maestría en Ciencias, Instituto de Genética Humana Dr. Enrique Corona Rivera, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Instituto de Desarrollo en Ciencia e Investigación Biomédica S.C., Guadalajara, Jalisco C.P. 44680, Mexico" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Consideraciones éticas en el diagnóstico presintomático de ataxias espinocerebelosas autosómico dominantes" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">With the introduction of molecular diagnosis and such programmes as the Human Genome Project, scientists expected great advances in different areas of knowledge, as well as the possibility of improving health. Primary objectives of medical genetics were clear: diagnosis, treatment, and prevention of genetic disorders.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">1</span></a> As a result, molecular diagnosis of such genetic disorders as Huntington disease (HD), Alzheimer disease, spinocerebellar ataxias (SCA), familial amyloid polyneuropathy, and other neurodegenerative disorders, has been possible for more than 30 years. This offered the opportunity to deliver presymptomatic diagnoses (PSD) and predictive diagnoses of some neurodegenerative diseases before any signs and symptoms are apparent.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">2,3</span></a> The ethical considerations of this possibility soon attracted attention, based on the controversy surrounding the benefits of ascertaining a person's susceptibility to a disease for which there is no curative treatment and whose clinical outcome cannot be modified.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">4,5</span></a> In the specific case of SCA, the European Molecular Genetics Quality Network (EMQN) drafted guidelines in 2010 describing requirements for performing presymptomatic analyses in accredited laboratories with the aim of providing a quality guarantee.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">6</span></a> However, there is no standard providing guidance on presymptomatic diagnosis in subjects at risk for presenting a disease. Currently, PSD is conducted according to general ethical guidelines and other guidelines issued for such diseases as HD.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Objective</span><p id="par0010" class="elsevierStylePara elsevierViewall">The objective is to analyse the ethical considerations, genetic counselling procedures, and recommendations derived from studies of PSD in subjects at risk for SCA.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Development</span><p id="par0015" class="elsevierStylePara elsevierViewall">Presymptomatic diagnosis is defined as the process of identifying healthy subjects who will develop a genetic disorder if they live long enough.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a> It was first used in 1983 to identify subjects at risk of developing HD.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">8</span></a> Based on its origin and inheritance pattern, SCA was included in the group of neurodegenerative diseases that can be diagnosed before patients present symptoms.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">9</span></a></p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Spinocerebellar ataxias</span><p id="par0020" class="elsevierStylePara elsevierViewall">Spinocerebellar ataxias are a group of neurodegenerative disorders with an autosomal dominant inheritance pattern. Their symptoms are caused by dysfunction of the cerebellum and brainstem, and of their pathways and associated connections.<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">10,11</span></a> The incidence of SCA is estimated at 2 to 3 cases per 100 000 population.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">12</span></a> Ruano et al.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">13</span></a> performed a meta-analysis which determined a prevalence of 0 to 5.6 cases per 100 000 population for autosomal dominant SCA. Similarly, Polo et al.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">14</span></a> identified a prevalence of 0.29 cases per 100 000 population in Cantabria. Since the disease was first identified, different classifications have been used, with the classification based on gene loci being the most widely accepted.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">15</span></a> More than 35 types have been described to date.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">16</span></a> The subset caused by CAG repeats (SCA1, SCA2, SCA3, SCA6, SCA7, SCA12, SCA17, and DPRLA) are worth mentioning since they are responsible for more than 50% of all cases. Other SCAs originate in different types of repeats, point mutations, and deletions.<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">17,18</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">On the clinical level, autosomal dominant SCAs are characterised by the presence of progressive cerebellar ataxia, which may be associated with ophthalmoplegia; pyramidal, extrapyramidal, and sensory signs; cognitive impairment; and peripheral neuropathy. Symptoms usually manifest in adults; however, several types show an anticipation phenomenon. Due to the clinical and genetic heterogeneity of this group of diseases, they should be identified by a molecular study of genomic DNA obtained from a blood sample.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">15</span></a> No curative treatments have been developed for this group of diseases. Current management focuses on treating symptoms and complications, in addition to appropriate genetic counselling offered by a multidisciplinary team.<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">19,20</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Methods</span><p id="par0030" class="elsevierStylePara elsevierViewall">With the aim of analysing the ethical considerations and genetic counselling procedures used in PSD for subjects at risk for SCA, we searched PubMed using the keywords ‘genetic counselling in SCA’ and ‘presymptomatic diagnosis and SCA’. Our search delivered 12 articles. We excluded those analysing PSD as part of a familial study, those lacking genetic counselling before the analysis, and those not clearly distinguishing between subjects at risk for SCA and those likely to develop other neurodegenerative diseases. Information was limited and only 6 studies met the inclusion criteria. We also searched for all articles cited as the basis for ethical considerations in these studies.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Studies</span><p id="par0035" class="elsevierStylePara elsevierViewall">All articles analysed in this review followed the guidelines available at that time for undertaking PSD during research. Given that other neurodegenerative disorders show similar clinical presentation and progression, some articles analysed more than one disease. Only Paul et al.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">21</span></a> and Cruz-Marino et al.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">22</span></a> included exclusively patients at risk for SCA3 and SCA2, respectively. Goizet et al.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">23</span></a> and Schuler-Faccini et al.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> studied subjects with risk of HD and SCA; Sequeiros et al. (1996 a,b; cited in Schuler-Faccini)<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> and Rodrigues et al.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">8</span></a> conducted their studies in subjects at risk for HD, SCA, and familial amyloid polyneuropathy. Although different diseases were analysed in each study, there were similarities between the PSD procedures described, which makes them comparable.</p><p id="par0040" class="elsevierStylePara elsevierViewall">One of the first points to consider in PSD is the right of any (asymptomatic) patient to remain unaware of his condition, especially when no treatment is available, since this knowledge will change the patient's self-perceived health. It may even harm patients by triggering catastrophic events, as has been observed in such diseases as HD.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">25</span></a> This being the case, good clinical practices in research and the guidelines issued by different organisations require an appropriate informed consent process prior to performing PSD. The consent document should highlight such important aspects as confidentiality, risks, benefits, study limitations, and others. Most of the studies analysed include signing an informed consent to be part of the genetic counselling process. In order to preserve patient confidentiality, it is important to reflect on where data are to be stored and whether they should be kept in separate files that will only be available to the interested party. Another point to consider is the maturity level of the patient receiving the information. However, each case will have to be examined individually to determine the subject's capacity. Subjects of legal age are generally thought to be prepared for this kind of decision; however, legal age differs from country to country, with a range of 14-21 years. For this reason, a consensus was reached to establish 18 years as the minimum age for participating in PSD.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">5</span></a> Only the study by Sequeiros et al.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> permitted an analysis of subjects aged 16 or older as part of a protocol for estimating reproductive risk. The minimum age for PSD may be a controversial issue, and analysing the subjects’ maturity levels prior to PSD is recommendable to ensure their well-being. Furthermore, every patient's right to decide freely whether they wish to know their health status should be respected. The PSD process should provide patients with the necessary tools to make the decision independently; having reached the age of 18 is used only as a reference.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Genetic counselling programmes</span><p id="par0045" class="elsevierStylePara elsevierViewall">Different programmes have been implemented and all of them are supported by multidisciplinary teams. Subjects must be able to receive the best quality genetic counselling and medical and psychological support to cope with PSD. With this in mind, the studies reviewed here included at least one geneticist and one psychologist. These professionals were responsible for providing information on the diagnosis, risks, prognosis, and medical details, as well as for assessing psychological well-being. Other studies also included genetic counsellors, psychiatrists, neurologists, nurses, and social workers. <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> presents detailed information about each study. The study by Schuler-Faccini et al. could be used to analyse how the same counselling programme was affected by changes to the multidisciplinary team, since they only included a geneticist, a psychologist, and a neurologist in the first stage. They later incorporated a genetic counsellor and a psychiatrist. This way, it is possible to compare the PSDs performed between 1999 and 2009 and those from the 2010 to 2012 period.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> There was a slight increase in the percentage of subjects willing to undergo PSD, as well as a significant increase in the percentage of patients who attended follow-up visits. No minimum number of specialties has been determined for the multidisciplinary team. In order to provide better care, the team should at the very least include a geneticist and a neurologist; these doctors will be responsible for such medical processes as diagnosis, clinical analysis, management, and treatment of the disease and its complications. Support from a psychologist, a psychiatrist, and a genetic counsellor is also necessary; these professionals will be responsible for determining the patient's maturity level, psychological integrity, and any risks derived from PSD. They also support patients as they cope with their diagnoses and accompany them during the process. However, other professionals, including nurses, social workers, and nutritionists, may also be needed to provide optimal genetic counselling services.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">According to the available guidelines, at least 3 counselling sessions should be completed before PSD to protect subjects from risks.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a> Based on the above, each study arranged for patients to have varying numbers of visits before PSD. A minimum of 2 sessions were scheduled. These offered counselling at the initial meeting, after which the sample was obtained. Results were delivered in a subsequent visit, as in the study by Goizet et al.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">23</span></a> Other studies such as those by Rodrigues et al.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">8</span></a> and Schuler-Faccini et al.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">24</span></a> opted for more conservative programmes which offered more in-depth care, with emphasis on analysing psychological integrity and risk. These programmes also provided the opportunity of resolving the disorders identified and subsequently taking a sample for PSD. They ended when results were delivered during the final visit. Wertz et al.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a> recommended holding 3 sessions before delivering results; however, this is not a set number, and each team should adapt it specifically according to the patient's psychological integrity to minimise the risks of catastrophic events.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Similarly, follow-up sessions following presentation of the results of the PSD are also recommended. Unlimited follow-up sessions are recommended for subjects with unfavourable test results, but also for those with normal results to alleviate survivor's guilt.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a> In accordance with these recommendations, the research articles we reviewed included follow-up programmes consisting of at least one visit after presenting the results with the exception of the study by Goizet et al.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">23</span></a>, which does not mention follow-up. Most authors designed their studies to include a follow-up programme of 3 to 4 visits (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), in addition to offering subsequent visits at the subjects’ request. However, the percentage of individuals reported by the studies to have attended the scheduled follow-up visits was 0%-49%, in the best case scenario. All reports suggest a low attendance rate for follow-up visits; however, no causes have been identified, except in the study by Cruz-Marino et al.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">22</span></a> Therefore, patients undergoing PSD testing should be informed of the importance of follow-up sessions, which afford the opportunity of remaining in contact to prevent complications and receive information on any new treatment options.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Guidelines on presymptomatic diagnoses</span><p id="par0060" class="elsevierStylePara elsevierViewall">The guidelines issued by the World Health Organization in 2003 recommend considering the following basic conditions before offering PSD testing: (i) guarantee confidentiality, (ii) inform the subject about the limitations of testing, (iii) ensure the subject has no mental disorder when the test is performed, (iv) examine evidence that the information provided by testing would be used to prevent harm to the tested individual, families, etc., and (v) ensure that testing is accompanied by a counselling programme appropriate for the disorder. Additionally, subjects should provide their informed consent.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">7</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">In the case of SCA, requirements have been issued by such organisations as the EMQN for PSD testing in accredited laboratories. Some of the most important requirements include the following: (i) no PSD should be offered to minors since it holds no advantages for them, (ii) joint documentation of the process by the genetic counselling service and the laboratory; (iii) all requests for PSD must be made through a genetic counselling service or be accompanied by a document stating that pre-test genetic counselling took place, (iv) written informed consent according to local and/or international regulations, and (v) there must be a confirmed diagnosis in the family.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">6</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Unlike in the case of SCA, the International Huntington Association (IHA) and the World Federation of Neurology (WFN) jointly issued guidelines for the predictive testing for Huntington disease in 1994.<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">26</span></a> These recommendations are successful as the minimum parameters to be considered in patients with HD, in addition to being useful in other neurodegenerative diseases such as frontotemporal dementia and SCA.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">5</span></a> Analysis of the information gathered in our review of these articles, together with useful existing guidelines for other diseases, could lay the groundwork for issuing specific recommendations for PSD in SCA. These recommendations may include making a register of results in order to analyse the benefits of these data at a later time.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conclusions</span><p id="par0075" class="elsevierStylePara elsevierViewall">Presymptomatic diagnosis of SCA is an opportunity for at-risk subjects to know if they will develop the disease in later life; it also helps them plan their families in light of this risk. Presymptomatic diagnosis should be performed following guidelines intended to safeguard subjects’ physical and psychological health. To date, there are no specific guidelines on performing PSD in patients at risk for SCA. PSD is currently undertaken following guidelines issued by international organisations and additional recommendations designed for other diseases. Implementing genetic counselling programmes is essential in all hospitals aiming to diagnose SCA before symptoms manifest. An ethics committee must approve, regulate, and ensure fulfilment of procedures used in PSD; the participation of the ministry of health and support from specialised organisations, where available, are also crucial. Whenever possible, molecular diagnosis of SCA should be performed exclusively in patients older than 18 with a clinical suspicion of the disease and a minimum risk of 50%, i.e., when one of the parents is affected. Furthermore, a genetic counselling programme including a multidisciplinary team of at least a geneticist, a neurologist, and a psychologist and/or a psychiatrist should be available.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Funding</span><p id="par0080" class="elsevierStylePara elsevierViewall">This article has received no public or private funding.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Conflicts of interest</span><p id="par0085" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres887291" "titulo" => "Abstract" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Development" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec873240" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres887292" "titulo" => "Resumen" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0020" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0025" "titulo" => "Desarrollo" ] 2 => array:2 [ "identificador" => "abst0030" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec873241" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Objective" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Development" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Spinocerebellar ataxias" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Studies" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Genetic counselling programmes" ] 4 => array:2 [ "identificador" => "sec0040" "titulo" => "Guidelines on presymptomatic diagnoses" ] ] ] 7 => array:2 [ "identificador" => "sec0045" "titulo" => "Conclusions" ] 8 => array:2 [ "identificador" => "sec0050" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Conflicts of interest" ] 10 => array:2 [ "identificador" => "xack296739" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2014-12-18" "fechaAceptado" => "2015-06-01" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec873240" "palabras" => array:5 [ 0 => "Genetic counsel" 1 => "Spinocerebellar ataxia" 2 => "Presymptomatic diagnosis" 3 => "Neurodegenerative disorders" 4 => "Ethics" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec873241" "palabras" => array:5 [ 0 => "Asesoramiento genético" 1 => "Ataxias espinocerebelosas" 2 => "Diagnóstico presintomático" 3 => "Trastornos neurodegenerativos" 4 => "Ética" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Information on achieving presymptomatic diagnosis of spinocerebellar ataxia (SCA) is limited. The advent of molecular diagnosis makes it possible to identify the carriers of different diseases and has also introduced the prospect of detecting diseases even before their onset. This has drawn attention to the ethical implications that must be considered in these subjects with a view to preserving their physical and psychological well-being.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Development</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">SCA is composed of a group of neurodegenerative disorders with autosomal dominant inheritance. Only a few publications have described the genetic counselling processes and guidelines to be followed during the process of presymptomatic diagnosis (PSD). The size of the multidisciplinary teams, their areas of expertise, and the number of counselling sessions are different for each of the studies analysed here. However, the basis of presymptomatic diagnosis originates in common guidelines to which members of our team have contributed recently.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Conclusion</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Presymptomatic diagnosis should be performed according to guidelines that safeguard the subjects’ welfare. The diagnostic process is only recommended for patients over 18 years old with symptoms suggesting SCA, and a minimum risk of 50%. Genetic counselling programmes must be available in all centres that offer presymptomatic diagnosis of SCA.</p></span>" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Development" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introducción</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Existe información limitada de la realización de diagnóstico presintomático en ataxias espinocerebelosas (SCA) autosómicas dominantes. La llegada del diagnóstico molecular, además de brindar la posibilidad de realizar identificación en pacientes portadores de distintas enfermedades, permitió también la posibilidad de detectar enfermedades incluso antes de su presentación. Esto atrajo la atención sobre las implicaciones éticas que deberían ser consideradas en estos sujetos, con la finalidad de salvaguardar su bienestar físico y psicológico.</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Desarrollo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La SCA está compuesta por un grupo de trastornos neurodegenerativos con patrón de herencia autosómico dominante. Existen pocas publicaciones que describen el proceso de asesoramiento y los lineamientos considerados durante el proceso de diagnóstico presintomático. El número de integrantes de los equipos multidisciplinarios, sus áreas de especialidad y número de sesiones durante el asesoramiento es variable en cada uno de los trabajos analizados. Sin embargo, las bases para su realización tienen origen en documentos comunes, en los cuales algunos de los autores han participado en fechas más recientes.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conclusiones</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">El diagnóstico presintomático debe ser realizado bajo lineamientos que salvaguarden el bienestar de los sujetos. Sería recomendable que el diagnóstico de SCA sea realizado solo a pacientes con clínica sugestiva, mayores de 18 años y con un riesgo mínimo del 50%. Deben estar disponibles esquemas de asesoramiento genético en todos aquellos centros que pretenden realizar diagnóstico de SCA antes de la presentación de síntomas.</p></span>" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0020" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0025" "titulo" => "Desarrollo" ] 2 => array:2 [ "identificador" => "abst0030" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Orozco-Gutiérrez MH, Cervantes-Aragón I, García-Cruz D. Consideraciones éticas en el diagnóstico presintomático de ataxias espinocerebelosas autosómico dominantes. Neurología. 2017;32:469–475.</p>" ] 1 => array:2 [ "etiqueta" => "☆☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">This study has not been presented at any of the SEN Annual Meetings or at any other events.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">EC, ethics committee; RRE, reproductive risk estimation; FAP, familial amyloid polyneuropathy; HD, Huntington disease; NAp, not applicable; NA, not available; SCA, spinocerebellar ataxia.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sequeiros et al.,<br>1996 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Paul et al.,<br>1999 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Goizet et al., 2002 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Rodrígues et al.,<br>2012 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cruz-Marino et al.,<br>2013 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Schuler-Faccini et al.,<br>2014 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">EC approval</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Informed consent</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Diseases</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">HD, SCA, and FAP</td><td class="td" title="table-entry " align="left" valign="top">SCA3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">HD and SCA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">HD, SCA, and FAP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">SCA2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="center" valign="top">HD and SCA</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Period</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Up to 1998 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1999-2009 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2001-2012 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1999-2009 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2010-2012 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Team</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Geneticist, neurologist, psychologist, clinical psychologist, genetic counsellor, psychiatrist, and social worker</td><td class="td" title="table-entry " align="left" valign="top">Geneticist, social psychologist \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Geneticist, neurologist, psychologist, social worker, and nurse \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Geneticist and psychologist \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Geneticist, genetic counsellor, nurse, and psychologist with an MS degree \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Geneticist, neurologist, and psychologist \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Geneticist, neurologist, psychologist, genetic counsellor, and psychiatrist \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Number of subjects at risk of SCA</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">236 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">153 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">768 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">147 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">116 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Inclusion criteria</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18 years or ><span class="elsevierStyleHsp" style=""></span>16 in cases of RRE<br>Risk of 50% and 25% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>years<br>Risk of 50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>years<br>Risk of 50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>years<br>Risk of 50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥<span class="elsevierStyleHsp" style=""></span>18<span class="elsevierStyleHsp" style=""></span>years<br>Risk of 50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Total sessions</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Session 1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling: diagnosis, outcome, risk, and medical considerations<br>1<span class="elsevierStyleHsp" style=""></span>st sample taken \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling: medical considerations and delivery of presymptomatic diagnosis<br>Sample taking \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling: diagnosis, outcome, risk, and medical considerations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling: medical considerations, psychological evaluation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling: diagnosis, outcome, risk \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Session 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Genetic counselling, Q and A, and information<br>2nd sample taken \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Delivery of results \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Determining psychological risks and resolution \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Psychiatric/psychological evaluation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Session 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Delivery of results \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Delivery of results \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Session 4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NAp \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sample taking \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Sample taking \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Session 5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Delivery of results \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Delivery of results \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Delivery of results during the visit</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2nd \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2nd \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2nd \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5th \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3rd \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5th \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Follow-up after delivery of results</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 weeks<br>6 months<br>12 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 week \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Not specified \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 weeks<br>6 months<br>12 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 week<br>4 weeks<br>6 months<br>12 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 weeks<br>6 months<br>12 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Patients agreeing to provide samples, n (%) (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">66 (27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(71) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">31 (67) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">85 (55) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(24) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">82 (55) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">81 (69) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Subjects receiving results, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(77) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(71) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 (87) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29 (93) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">74 (87) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">75 (91) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(90) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Subjects attending follow-up, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(49) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(24) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19 (65) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">NA \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(31) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1499319.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Comparison of the characteristics of the studies focusing on presymptomatic diagnosis of subjects with risk of SCA.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bib0135" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "91 p" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hereditary Diseases Programme. Guidelines on ethical issues in medical genetics and the provision of genetics services" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "World Health Organization" "etal" => false "autores" => array:4 [ 0 => "D.C. Wertz" 1 => "J.C. Fletcher" 2 => "K. Berg" 3 => "V. Boulyjenkov" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "1995" "editorial" => "World Health Organization" "editorialLocalizacion" => "Geneva" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0140" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Wiggins" 1 => "P. Whyte" 2 => "M. Huggins" 3 => "S. Adam" 4 => "J. Theilmann" 5 => "M. Bloch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199211123272001" "Revista" => array:6 [ "tituloSerie" => "New Engl J Med" "fecha" => "1992" "volumen" => "327" "paginaInicial" => "1401" "paginaFinal" => "1405" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1406858" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0145" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Kawaguchi" 1 => "T. Okamoto" 2 => "M. Taniwaki" 3 => "M. Aizawa" 4 => "M. Inoue" 5 => "S. Katayama" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ng1194-221" "Revista" => array:6 [ "tituloSerie" => "Nat Genet" "fecha" => "1994" "volumen" => "8" "paginaInicial" => "221" "paginaFinal" => "228" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7874163" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0150" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ataxia espinocerebelosa tipo 2: una experiencia en la rehabilitación psicológica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Paneque-Herrera" 1 => "A.R. Reynaldo" 2 => "L. Velázquez-Pérez" 3 => "F.N. Santos" 4 => "H.E. Miranda" 5 => "P.N. Real" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "2001" "volumen" => "33" "paginaInicial" => "1001" "paginaFinal" => "1005" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11785023" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0155" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for the predictive genetic test in Huntington's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. MacLeod" 1 => "A. Tibben" 2 => "M. Frontali" 3 => "G. Evers-Kiebooms" 4 => "A. Jones" 5 => "A. Martinez-Descales" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1399-0004.2012.01900.x" "Revista" => array:6 [ "tituloSerie" => "Clin Genet" "fecha" => "2013" "volumen" => "83" "paginaInicial" => "221" "paginaFinal" => "231" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22642570" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0160" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EMQN Best Practice Guidelines for molecular genetic testing of SCAs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Sequeiros" 1 => "J. Martindale" 2 => "S. Seneca" 3 => "P. Giunti" 4 => "O. Kamarainen" 5 => "V. Volpini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ejhg.2010.8" "Revista" => array:6 [ "tituloSerie" => "Eur J Hum Genet" "fecha" => "2010" "volumen" => "18" "paginaInicial" => "1173" "paginaFinal" => "1176" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20179742" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0165" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WHO Human Genetics Programme. Review of ethical issues in medical genetics: report of consultants to WHO" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.C. Wertz" 1 => "G.F. Fletcher" 2 => "K. Berg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:4 [ "fecha" => "2003" "paginaInicial" => "102" "editorial" => "World Health Organization" "editorialLocalizacion" => "Geneva" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0170" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Presymptomatic testing for neurogenetic diseases in Brazil: Assessing who seeks and who follows through with testing" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.S. Rodrigues" 1 => "V.Z. de Oliveira" 2 => "G. Camargo" 3 => "C.M. Osorio" 4 => "R.M. de Castilhos" 5 => "M.L. Saraiva-Pereira" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10897-011-9383-8" "Revista" => array:6 [ "tituloSerie" => "J Genet Couns" "fecha" => "2012" "volumen" => "21" "paginaInicial" => "101" "paginaFinal" => "112" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21717286" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0175" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ataxia espinocerebelosa tipo 2: aceptación del diagnóstico prenatal en descendientes en riesgo" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Paneque-Herrera" 1 => "F.N. Santos" 2 => "C.H.V. Tamayo" 3 => "A.R. Reynaldo" 4 => "L. Velázquez-Pérez" 5 => "L.E. Almaguer-Mederos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "2001" "volumen" => "33" "paginaInicial" => "904" "paginaFinal" => "908" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11784998" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0180" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluación neurofisiológica en pacientes afectados por ataxia espinocerebelosa tipo 2" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Velázquez-Pérez" 1 => "E.E. Medina" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Neurol" "fecha" => "1998" "volumen" => "27" "paginaInicial" => "921" "paginaFinal" => "926" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9951005" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0185" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical neurogenetics: autosomal dominant spinocerebellar ataxia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "V.G. Shakkottai" 1 => "B.L. Fogel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ncl.2013.04.006" "Revista" => array:6 [ "tituloSerie" => "Neurol Clin" "fecha" => "2013" "volumen" => "31" "paginaInicial" => "987" "paginaFinal" => "1007" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24176420" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0190" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autosomal dominant cerebellar ataxia type I: A review of the phenotypic and genotypic characteristics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N.R. Whaley" 1 => "S. Fujioka" 2 => "Z.K. Wszolek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-1172-6-33" "Revista" => array:5 [ "tituloSerie" => "Orphanet J Rare Dis" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21619691" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0195" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The global epidemiology of hereditary ataxia and spastic paraplegia: A systematic review of prevalence studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Ruano" 1 => "C. Melo" 2 => "M.C. Silva" 3 => "P. Coutinho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000358801" "Revista" => array:6 [ "tituloSerie" => "Neuroepidemiology" "fecha" => "2014" "volumen" => "42" "paginaInicial" => "174" "paginaFinal" => "183" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24603320" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0200" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.M. Polo" 1 => "J. Calleja" 2 => "O. Combarros" 3 => "J. Berciano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:8 [ "tituloSerie" => "Brain" "fecha" => "1991" "volumen" => "114" "numero" => "Pt 2" "paginaInicial" => "855" "paginaFinal" => "866" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2043954" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1470204514702633" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0205" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autosomal dominant cerebellar ataxias: Polyglutamine expansions and beyond" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Durr" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1474-4422(10)70183-6" "Revista" => array:6 [ "tituloSerie" => "Lancet Neurol" "fecha" => "2010" "volumen" => "9" "paginaInicial" => "885" "paginaFinal" => "894" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20723845" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0210" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "OMIM. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biochnology Information, National Library of Medicine (Bethesda, MD). 2014. [accessed 28 Dec 2014]. Available from: <a href="http://www3.ncbi.nlm.nih.gov/omim/2014">http://www3.ncbi.nlm.nih.gov/omim/2014.</a>" ] ] ] 16 => array:3 [ "identificador" => "bib0215" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis and management of early- and late-onset cerebellar ataxia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Brusse" 1 => "J.A. Maat-Kievit" 2 => "J.C. van Swieten" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1399-0004.2006.00722.x" "Revista" => array:6 [ "tituloSerie" => "Clin Genet" "fecha" => "2007" "volumen" => "71" "paginaInicial" => "12" "paginaFinal" => "24" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17204042" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0220" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Sequeiros" 1 => "S. Seneca" 2 => "J. Martindale" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ejhg.2010.10" "Revista" => array:6 [ "tituloSerie" => "Eur J Hum Genet" "fecha" => "2010" "volumen" => "18" "paginaInicial" => "1188" "paginaFinal" => "1195" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20179748" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0225" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Machado-Joseph disease: From first descriptions to new perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Bettencourt" 1 => "M. Lima" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-1172-6-35" "Revista" => array:5 [ "tituloSerie" => "Orphanet J Rare Dis" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "35" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21635785" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0230" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Milestones in ataxia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T. Klockgether" 1 => "H. Paulson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/mds.23559" "Revista" => array:6 [ "tituloSerie" => "Mov Disord" "fecha" => "2011" "volumen" => "26" "paginaInicial" => "1134" "paginaFinal" => "1141" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21626557" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0235" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Living with Machado-Joseph disease in a small rural community of the Tagus valley" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Paul" 1 => "I. Martin" 2 => "M. do Rosario Silva" 3 => "M. Silva" 4 => "P. Coutinho" 5 => "J. Sequeiros" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "16211" "Revista" => array:7 [ "tituloSerie" => "Community Genet" "fecha" => "1999" "volumen" => "2" "paginaInicial" => "190" "paginaFinal" => "195" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14960841" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016508513014947" "estado" => "S300" "issn" => "00165085" ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0240" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Cuban program for predictive testing of SCA2: 11 years and 768 individuals to learn from" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Cruz-Marino" 1 => "L. Velazquez-Perez" 2 => "Y. Gonzalez-Zaldivar" 3 => "R. Aguilera-Rodriguez" 4 => "M. Velazquez-Santos" 5 => "Y. Vazquez-Mojena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/cge.12142" "Revista" => array:6 [ "tituloSerie" => "Clin Genet" "fecha" => "2013" "volumen" => "83" "paginaInicial" => "518" "paginaFinal" => "524" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23495852" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0245" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "French Group for Presymptomatic Testing in Neurogenetic Disorders" "etal" => false "autores" => array:3 [ 0 => "C. Goizet" 1 => "G. Lesca" 2 => "A. Durr" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Neurology" "fecha" => "2002" "volumen" => "59" "paginaInicial" => "1330" "paginaFinal" => "1336" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12427879" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0250" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genetic counseling and presymptomatic testing programs for Machado-Joseph Disease: lessons from Brazil and Portugal" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Schuler-Faccini" 1 => "C.M. Osorio" 2 => "F. Romariz" 3 => "M. Paneque" 4 => "J. Sequeiros" 5 => "L.B. Jardim" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Genet Mol Biol" "fecha" => "2014" "volumen" => "37" "numero" => "1 Suppl" "paginaInicial" => "263" "paginaFinal" => "270" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24764760" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0255" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "E.W. Almqvist" 1 => "M. Bloch" 2 => "R. Brinkman" 3 => "D. Craufurd" 4 => "M.R. Hayden" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Hum Gen" "fecha" => "1999" "volumen" => "64" "paginaInicial" => "1293" "paginaFinal" => "1304" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0260" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "International Huntington Association and the World Federation of Neurology Research Group on Huntington's, Chorea., Guidelines for the molecular genetics predictive test in Huntington's disease" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Med Genet" "fecha" => "1994" "volumen" => "31" "paginaInicial" => "555" "paginaFinal" => "559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7966192" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack296739" "titulo" => "Acknowledgements" "texto" => "<p id="par0090" class="elsevierStylePara elsevierViewall">We would like to thank Dr María Cristina Moran Moguel.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/21735808/0000003200000007/v1_201708280004/S2173580817300652/v1_201708280004/en/main.assets" "Apartado" => array:4 [ "identificador" => "9423" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735808/0000003200000007/v1_201708280004/S2173580817300652/v1_201708280004/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580817300652?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 10 | 1 | 11 |
| 2024 October | 31 | 6 | 37 |
| 2024 September | 44 | 6 | 50 |
| 2024 August | 32 | 2 | 34 |
| 2024 July | 24 | 2 | 26 |
| 2024 June | 26 | 1 | 27 |
| 2024 May | 15 | 4 | 19 |
| 2024 April | 22 | 4 | 26 |
| 2024 March | 19 | 3 | 22 |
| 2024 February | 21 | 8 | 29 |
| 2024 January | 28 | 13 | 41 |
| 2023 December | 27 | 18 | 45 |
| 2023 November | 23 | 16 | 39 |
| 2023 October | 19 | 18 | 37 |
| 2023 September | 11 | 12 | 23 |
| 2023 August | 17 | 15 | 32 |
| 2023 July | 11 | 21 | 32 |
| 2023 June | 16 | 14 | 30 |
| 2023 May | 17 | 20 | 37 |
| 2023 April | 26 | 13 | 39 |
| 2023 March | 23 | 14 | 37 |
| 2023 February | 28 | 12 | 40 |
| 2023 January | 34 | 21 | 55 |
| 2022 December | 19 | 16 | 35 |
| 2022 November | 35 | 22 | 57 |
| 2022 October | 21 | 21 | 42 |
| 2022 September | 24 | 14 | 38 |
| 2022 August | 28 | 6 | 34 |
| 2022 July | 37 | 9 | 46 |
| 2022 June | 46 | 8 | 54 |
| 2022 May | 68 | 6 | 74 |
| 2022 April | 117 | 12 | 129 |
| 2022 March | 177 | 11 | 188 |
| 2022 February | 180 | 3 | 183 |
| 2022 January | 86 | 6 | 92 |
| 2021 December | 74 | 10 | 84 |
| 2021 November | 90 | 14 | 104 |
| 2021 October | 25 | 8 | 33 |
| 2021 September | 21 | 8 | 29 |
| 2021 August | 21 | 10 | 31 |
| 2021 July | 17 | 4 | 21 |
| 2021 June | 17 | 8 | 25 |
| 2021 May | 20 | 14 | 34 |
| 2021 April | 47 | 5 | 52 |
| 2021 March | 29 | 13 | 42 |
| 2021 February | 23 | 6 | 29 |
| 2021 January | 24 | 8 | 32 |
| 2020 December | 23 | 11 | 34 |
| 2020 November | 19 | 5 | 24 |
| 2020 October | 14 | 7 | 21 |
| 2020 September | 22 | 14 | 36 |
| 2020 August | 30 | 4 | 34 |
| 2020 July | 23 | 10 | 33 |
| 2020 June | 18 | 11 | 29 |
| 2020 May | 21 | 12 | 33 |
| 2020 April | 20 | 5 | 25 |
| 2020 March | 37 | 3 | 40 |
| 2020 February | 13 | 5 | 18 |
| 2020 January | 98 | 11 | 109 |
| 2019 December | 30 | 8 | 38 |
| 2019 November | 17 | 8 | 25 |
| 2019 October | 17 | 6 | 23 |
| 2019 September | 7 | 6 | 13 |
| 2019 August | 13 | 3 | 16 |
| 2019 July | 22 | 16 | 38 |
| 2019 June | 43 | 29 | 72 |
| 2019 May | 127 | 43 | 170 |
| 2019 April | 18 | 22 | 40 |
| 2019 March | 8 | 9 | 17 |
| 2019 February | 13 | 6 | 19 |
| 2019 January | 5 | 9 | 14 |
| 2018 December | 2 | 2 | 4 |
| 2018 November | 8 | 3 | 11 |
| 2018 October | 17 | 7 | 24 |
| 2018 September | 8 | 4 | 12 |
| 2018 August | 6 | 4 | 10 |
| 2018 July | 8 | 3 | 11 |
| 2018 June | 14 | 2 | 16 |
| 2018 May | 21 | 5 | 26 |
| 2018 April | 3 | 1 | 4 |
| 2018 March | 10 | 1 | 11 |
| 2018 February | 2 | 3 | 5 |
| 2018 January | 14 | 1 | 15 |
| 2017 December | 18 | 0 | 18 |
| 2017 November | 23 | 1 | 24 |
| 2017 October | 12 | 2 | 14 |
| 2017 September | 27 | 6 | 33 |
| 2017 August | 3 | 3 | 6 |
| 2017 July | 0 | 2 | 2 |
| 2017 June | 1 | 1 | 2 |
| 2017 May | 2 | 4 | 6 |
| 2017 April | 2 | 4 | 6 |
Show all
